Current fluoroquinolone susceptibility criteria for Salmonella needs Re-evaluation

Kathmandu University Medical Journal

Volumn 10, Issue 37, 2012, Pages 24-29

  Acharya, D ^a   Malla, S ^b   Bhatta, D R ^a   Adhikari, N ^a   Dumre, S P ^b,c  

^a TRIBHUVAN UNIVERSITY   (Nepal)

^b National Public Health Laboratory   (Nepal)

^c THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Enteric fever; Nepal; Reduced FQ susceptibility; Salmonella

Indexed keywords

CIPROFLOXACIN; NALIDIXIC ACID; OFLOXACIN; QUINOLONE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; DISK DIFFUSION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; SALMONELLA ENTERICA; SENSITIVITY AND SPECIFICITY; SEROTYPE;

EID: 84866752447     PISSN: 18122027     EISSN: 18122078     Source Type: Journal    
DOI: 10.3126/kumj.v10i1.6909     Document Type: Article

References (30)

1. Bhan MK, Bahl R, Bhatnagar S. Typhoid and paratyphoid fever. Lancet. 2005;366:749-762.
2. Crump JA, Luby SP, Mintz ED. The global burden of typhoid fever. Bull World Health Organ. 2004;82:346-353.
3. Parry CM, Hien TT, Dougan G, White NJ, Farrar JJ. Typhoid fever. N Engl J Med. 2002;347:1770-1782.
4. World Health Organization (WHO). Background document: The diagnosis, treatment and prevention of typhoid fever. WHO/ V&B/03.07. Geneva: World Health Organization. 2003.
5. Bhutta ZA. Current concepts in the diagnosis and treatment of typhoid fever. BMJ. 2006;333:78-82.
6. Threlfall EJ, Ward LR, Rowe B. Widespread occurrence of multiple drug-resistant Salmonella typhi in India. Eur J Clin Microbiol Infect Dis 1992;11:990-993.
7. Molbak K, Gerner-Smidt P, Wegener HC. Increasing quinolone resistance in Salmonella enterica serotype Enteritidis. Emerg Infect Dis. 2002;5:514-515.
8. Hakanen A, Kotilainen P, Jalava J, Siitonen A, Huovinen P. Detection of decreased fluoroquinolone susceptibility in salmonellas and validation of nalidixic acid screening test. J Clin Microbiol. 1999;37:3572-3577.
9. Threlfall EJ, Skinner JA, Ward LR. Detection of decreased in vitro susceptibility to ciprofloxacin in Salmonella enterica serotypes Typhi and Paratyphi A. J Antimicrob Chemother. 2001;48:740-741.
10. Nkemngu NJ, Asonganyi EDN, Njunda AL. Treatment failure in a typhoid patient infected with nalidixic acid resistant S. enterica serovar Typhi with reduced susceptibility to Ciprofloxacin: a case report from Cameroon. BMC Infect Dis. 2005;2(5):49.
11. Rupali P, Abraham OC, Jesudason MV, John TJ, Zachariah A, Sivaram S. Treatment failure in typhoid fever with ciprofloxacin susceptible Salmonella enterica serotype Typhi. Diagn Microbiol Infect Dis. 2004;49:1-3.
12. Piddock LJV, Griggs DJ, Hall MC, Jin YF. Ciprofloxacin resistance in clinical isolates of Salmonella typhimurium obtained from two patients. Antimicrob Agents Chemother. 1993;37:662-666.
13. Clinical Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing, 16th Informational Supplement, vol. 26. CLSI Document M100-S16. Wayne, 2006; PA: CLSI.
14. Aarestrup FM, Wiuff C, Molbak K, Threlfall EJ. Is it time to change fluoroquinolone breakpoints for Salmonella spp.? (Letter). Antimicrob Agents Chemother. 2003;47:827-829.
15. Crump JA, Barrett TJ, Nelson JT, Angulo FJ. Reevaluating fluoroquinolone breakpoints for Salmonella enterica serotype Typhi and for non-typhi salmonellae. Clin Infect Dis. 2003;37:75-81.
16. Albayrak F, Cokca F, Erdem B, Aysev AD. Predictive value of nalidixic acid resistance for detecting salmonellae with decreased ciprofloxacin susceptibility. Int J Antimicrob Agents. 2004;23:332-336.
17. Oteo J, Aracil B, Alos JI, Gomez-Garces JL. High rate of resistance to nalidixic acid in Salmonella enterica: Its role as a marker of resistance to fluoroquinolones. Clin Microbiol Infect. 2000;6:265-282.
18. Lewis J, Serichantalergs O, Pitarangsi C, Chuanak N, Mason CJ, Regmi LR, et al. Typhoid fever: a massive, single-point source, multidrug-resistant outbreak in Nepal. Clin Infect Dis. 2005;40:554-561.
19. Pokharel BM, Koirala J, Dahal RK, Mishra SK, Khadga PK, Tuladhar NR. Multidrug-resistant and extended-spectrum beta-lactamase (ESBL)- producing Salmonella enterica (serotypes Typhi and Paratyphi A) from blood isolates in Nepal: surveillance of resistance and a search for newer alternatives. Int J Infect Dis. 2006;10:434-438.
20. Malla S, Dumre SP. Changing trend of antimicrobial resistance toward Salmonella isolates of Nepal: findings of antimicrobial resistance surveillance program, Nepal. Int J Infect Dis. 2008;12:414-415.
21. Maskey AP, Basnyat B, Thwaites GE, Campbell JI, Farrar JJ, Zimmerman MD. Emerging trends in enteric fever in Nepal: 9124 cases confirmed by blood culture 1993-2003. Trans R Soc Trop Med Hyg. 2008;102:91-95.
22. Acharya D, Malla S, Bhatta DR, Dumre SP. Multidrug Resistant Salmonella enterica serovar Typhi. J Nepal Med Assoc. 2009;48(174):196-197.
23. Chau TT, Campbell JI, Galindo CM, Nguyan van MH, Diep TS, Nga TTT, et al. Antimicrobial Drug Resistance of Salmonella enterica serovar Typhi in Asia and molecular mechanism of reduced susceptibility to fluoroquinolones. Antimicrob Agents Chemother. 2007;51(12):4315-4323.
24. Bauer AW, Kirby WM, Sherries JC, Truck M. Antibiotic susceptibility testing by a single method. Am J Clin Pathol. 1995;45:493-496.
25. Khanal B, Sharma SK, Bhattacharya SK, Bhattarai NR, Deb M, Kanungo R. Antimicrobial susceptibility patterns of Salmonella enterica serotype Typhi in eastern Nepal. J Health Popul Nutr. 2007;25(1):82-7.
26. Hirose K, Hashimoto A, Tamura K, Kawamura Y, Ezaki T, Sagara H, et al. DNA sequence analysis of DNA gyrase and DNA topisomerase IV quinolone resistance-determining regions of Salmonella enterica serovar Typhi and serovar Paratyphi A. Antimicrob Agents Chemother. 2002;46:3249-3252.
27. Cloeckaert A, Chaslus-Dancla E. Mechanism of quinolone resistance in Salmonella. Vet Res. 2001;32:291-300.
28. Hooper DC. Mechanisms of fluoroquinolone resistance. Emerg Infect Dis. 2001;7:337-341.
29. Rodrigues C, Kumar NJ, Lalwani J, Mehta A. Ciprofloxacin breakpoints in enteric fever - time to revise our susceptibility criteria. Indian J Med Microbiol 2008;26:91.
30. Andrews JM. BSAC standardized disc susceptibility testing method (version 7). J Antimicrobiol Chemother. 2008;62:256-278.